Literature DB >> 12374671

Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung.

Nobuhiko Seki1, Tasaburo Takasu, Koichi Mandai, Masao Nakata, Hideyuki Saeki, Yuji Heike, Ichiro Takata, Yoshihiko Segawa, Toshiaki Hanafusa, Kenji Eguchi.   

Abstract

The overexpression of eukaryotic initiation factor 4E (eIF4E), a key regulator of protein synthesis, is involved in the malignant progression of various human cancers. We investigated eIF4E expression in atypical adenomatous hyperplasia (AAH) and adenocarcinomas of the human peripheral lung. On the basis of the WHO criteria with minor modifications, adenocarcinomas were classified as bronchioloalveolar carcinoma (BAC), mixed subtypes with a bronchioloalveolar pattern and minor invasion (early MX), and mixed subtypes with a papillary pattern and marked invasion (overt MX). eIF4E immunohistochemistry was performed in 143 tissue samples (31 AAH, 38 BAC, 43 early MX, and 31 overt MX). Both tumoral and stromal eIF4E levels were elevated from AAH, BAC, and early MX to overt MX and significantly associated with histological grade (P < 0.001 and P < 0.001, respectively). Tumoral and stromal eIF4E staining intensities were significantly correlated (P < 0.01). Immunoblot analysis of 51 tissue samples (2 AAH, 11 BAC, 18 early MX, and 20 overt MX) demonstrated that eIF4E expression in adenocarcinomas was 3.4-7.4-fold higher than in normal lung and that its expression progressively increased in the following order: AAH (lowest expression), BAC, early MX, and overt MX (highest expression). Multiple regression analysis revealed that both tumoral and stromal eIF4E expressions were significant independent factors for the histological subtype (P < 0.01 and P < 0.01, respectively). These results suggest that translational control is dysregulated during the development of peripheral lung adenocarcinoma and that progressive increases of tumoral and stromal eIF4E may be part of a positive feedback loop for malignant progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374671

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

Review 1.  A review of the association between osteosarcoma metastasis and protein translation.

Authors:  T S Osborne; C Khanna
Journal:  J Comp Pathol       Date:  2012-01-31       Impact factor: 1.311

2.  Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors.

Authors:  Cleo Y F Lee; Luke X X Bu; Arrigo DeBenedetti; B Jill Williams; Paul S Rennie; William W G Jia
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 3.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

4.  Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.

Authors:  Naghma Khan; Farrukh Afaq; Fatima H Khusro; Vaqar Mustafa Adhami; Yewseok Suh; Hasan Mukhtar
Journal:  Int J Cancer       Date:  2011-08-26       Impact factor: 7.396

5.  Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.

Authors:  H Awaya; Y Takeshima; O Furonaka; N Kohno; K Inai
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 6.  mTOR in Lung Neoplasms.

Authors:  Ildiko Krencz; Anna Sebestyen; Andras Khoor
Journal:  Pathol Oncol Res       Date:  2020-02-03       Impact factor: 3.201

7.  Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer.

Authors:  Akihiko Yoshizawa; Junya Fukuoka; Shigeki Shimizu; Konstantin Shilo; Teri J Franks; Stephen M Hewitt; Takeshi Fujii; Carlos Cordon-Cardo; Jin Jen; William D Travis
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

8.  Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.

Authors:  Antonello Punturieri; Eva Szabo; Thomas L Croxton; Steven D Shapiro; Steven M Dubinett
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

Review 9.  The oncogene eIF4E: using biochemical insights to target cancer.

Authors:  Martin Carroll; Katherine L B Borden
Journal:  J Interferon Cytokine Res       Date:  2013-03-08       Impact factor: 2.607

10.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Authors:  Biljana Culjkovic; Katherine L Borden
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.